Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
Colorcon
Medtronic
Merck

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ibudilast

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ibudilast?

Ibudilast is an investigational drug.

There have been 17 clinical trials for Ibudilast. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2019.

The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).

There are six hundred and ninety-four US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for Ibudilast
TitleSponsorPhase
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNovaPhase 2/Phase 3
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersMediciNovaPhase 1
Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBMMediciNovaPhase 1/Phase 2

See all Ibudilast clinical trials

Clinical Trial Summary for Ibudilast

Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast

See all Ibudilast clinical trials

US Patents for Ibudilast

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ibudilast   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Ibudilast   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
Ibudilast   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
Ibudilast   Start Trial Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag The Catholic University of America (Washington, DC)   Start Trial
Ibudilast   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Ibudilast   Start Trial Melanocortin-1 receptor-specific cyclic hexapeptides Palatin Technologies, Inc. (Cranbury, NJ)   Start Trial
Ibudilast   Start Trial Pyrazolopyridines and pyrazolopyrimidines Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ibudilast

Drugname Country Document Number Estimated Expiration Related US Patent
Ibudilast Canada 2961033 2034-09-11   Start Trial
Ibudilast European Patent Office 3192791 2034-09-11   Start Trial
Ibudilast Japan WO2016039408 2034-09-11   Start Trial
Ibudilast World Intellectual Property Organization (WIPO) 2016039408 2034-09-11   Start Trial
Ibudilast Australia 2012222348 2031-03-01   Start Trial
Ibudilast Australia 2012222351 2031-03-01   Start Trial
Ibudilast Australia 2013224959 2031-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.